Telmisartan vs. Perindopril in Mild-Moderate Alzheimer’s Disease Patients (SARTAN-AD) trial
Interventional Study
Get in touch about this studyWhat is the study about?
The SARTAN-AD study is comparing the effects of two approved medications for high blood pressure – Telmisartan and Perindopril – on their ability to maintain brain function in people with mild to moderate Alzheimer’s disease.
Eligibility–Who can participate?
Participants must:
- Be 50 years of age or older
- Have a diagnosis of Alzheimer’s disease
- Have had a previous MRI or CT brain scan
- Have a study partner who can come to all study visits
Time requirement:
- Screening visit
- In-person—3 hours
- Phone/Email – 10 min
- In-Person MRI -1 hour
- Baseline visit (in person)—4 hours
- Week 2 follow-up (phone or in person)—15-30 mins
- Month 1 follow-up (in person)—1 hour
- Month 3 follow-up (phone or in person)—1 hour
- Month 6 follow-up (in person)—4 hours
- Month 9 follow-up (phone or in person)—1 hour
- Month 12 follow-up (in person)—5 hours
TDRA investigator
Drs. Sandra Black and Sanjeev Kumar
More information
https://clinicaltrials.gov/ct2/show/NCT02085265
TDRA Site:
Centre for Addiction and Mental Health (CAMH)
Address: 1001 Queen St W, Toronto, ON M6J 1H4
Sunnybrook Health Sciences CentreAddress: 2075 Bayview Ave, Toronto, ON M4N 3M5
Age Group:
50 - 54, 55 - 59, 60 - 64, 65 - 69, 70 - 80, 81 - 85, 86 - 90, 91+